Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
about
Age-related neuroinflammatory changes negatively impact on neuronal functionThe promise of neuroprotective agents in Parkinson's diseaseAnti-inflammatory drugs and risk of Parkinson disease: A meta-analysisAn overview of clinical pharmacology of IbuprofenNon-steroidal anti-inflammatory drugs as disease-modifying agents for Parkinson's disease: evidence from observational studiesUse of ibuprofen and risk of Parkinson diseaseNeuroprotective and Therapeutic Strategies against Parkinson's Disease: Recent PerspectivesMyeloid Dendritic Cells are Potential Players in Human Neurodegenerative DiseasesInsights into Neuroinflammation in Parkinson's Disease: From Biomarkers to Anti-Inflammatory Based TherapiesNeuroinflammation in the pathophysiology of Parkinson's disease and therapeutic evidence of anti-inflammatory drugsRole of prostaglandins in neuroinflammatory and neurodegenerative diseasesUncovering novel actors in astrocyte-neuron crosstalk in Parkinson's disease: the Wnt/β-catenin signaling cascade as the common final pathway for neuroprotection and self-repairNeuroprotective and symptomatic effects of targeting group III mGlu receptors in neurodegenerative diseaseDNA variants in CACNA1C modify Parkinson disease risk only when vitamin D level is deficient.Microglia development and functionEstrogen ameliorates microglial activation by inhibiting the Kir2.1 inward-rectifier K(+) channel.Friend or foe: the dichotomous impact of T cells on neuro-de/re-generation during aging50th anniversary of the discovery of ibuprofen: an interview with Dr Stewart AdamsCNS infections, sepsis and risk of Parkinson's diseaseGene-environment interactions: key to unraveling the mystery of Parkinson's diseaseParkinson's disease research in a prospective cohort in ChinaRotenone and paraquat do not directly activate microglia or induce inflammatory cytokine releasePACAP deficiency sensitizes nigrostriatal dopaminergic neurons to paraquat-induced damage and modulates central and peripheral inflammatory activation in miceEarly neurodegeneration progresses independently of microglial activation by heparan sulfate in the brain of mucopolysaccharidosis IIIB miceStriatal neuroinflammation promotes Parkinsonism in ratsThe expression and release of Hsp60 in 6-OHDA induced in vivo and in vitro models of Parkinson's diseaseGenomic determinants of motor and cognitive outcomes in Parkinson's diseaseCommon genetic variation in the HLA region is associated with late-onset sporadic Parkinson's disease.Validation of secondary data sources to identify Parkinson disease against clinical diagnostic criteriaTyrosine hydroxylase gene: another piece of the genetic puzzle of Parkinson's diseaseSynergistic dopaminergic neurotoxicity of manganese and lipopolysaccharide: differential involvement of microglia and astroglia.Molecular Targets for PET Imaging of Activated Microglia: The Current Situation and Future Expectations.Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic interventionControl of neuroinflammation as a therapeutic strategy for amyotrophic lateral sclerosis and other neurodegenerative disordersIn vivo evaluation of microglia activation by intracranial iron overload in central pain after spinal cord injuryBrain arachidonic acid cascade enzymes are upregulated in a rat model of unilateral Parkinson diseaseSmoking duration, intensity, and risk of Parkinson diseaseTargeting Wnt signaling at the neuroimmune interface for dopaminergic neuroprotection/repair in Parkinson's disease.Cyclooxygenase and neuroinflammation in Parkinson's disease neurodegeneration.An exploratory study on CLU, CR1 and PICALM and Parkinson disease
P2860
Q21128630-B3709136-5A8C-4E1B-8FBB-94EF968E5BF0Q21129436-F17A9A71-1FAD-42EC-84E0-B7B6977BECA8Q22241651-C8D5CBC7-1023-48B8-B9C0-480947159597Q23724883-5E8C8772-A21E-4A42-B19D-22607664C480Q24235107-AD411723-6085-4850-B053-1EA3E132EDCBQ24594751-C45FB86D-7F75-424D-9012-6E07B4240E51Q26747508-9BA11B2C-4865-4EAC-9D25-E283BC07D733Q26770676-D544B7D2-9DBB-40A0-A8C6-54F13C1E1F51Q26795984-16DE12E6-821E-4E07-8B74-057BB512BD19Q26801035-848C81EE-DBF7-4507-8542-26ED32E14D24Q26863534-3954199C-D162-4D73-9781-0548D4876B3CQ26865502-EC3587E0-EF8B-4873-B6F1-DAAAE7B38D7DQ26995351-9BBA1299-E1C7-4401-9978-24A08E5B1781Q27312297-4581EBD4-77AE-4ED6-A318-32791B5D1B52Q27316453-E53E51BB-DFF7-4B30-BD02-223F57720CB6Q27333476-CA1BAD22-20A0-4BC1-8C1C-BA0D9AB27D38Q28077869-80315154-FA14-4863-8ECE-773D93845C1EQ28253389-89C852F9-B8CB-4143-8D12-059F17EDD5E7Q28387937-EB0E16E7-79D6-41E4-9C54-CC2558FF0F7CQ28388674-0ADFA6F0-21CA-46E1-8462-8FEFB79607BCQ28389811-E24D303E-A241-47D8-AC6B-17B09C2F45C4Q28392767-117009C3-F489-43E6-BAE9-86D3D2DF7BBDQ28397422-19D5C339-B53C-4326-9FFC-3F0BED2BD016Q28472880-F56881FA-06A4-4568-9D5C-9E81BEA5D881Q28475466-C5A9068F-25C0-481A-89DD-4F2244B9D48BQ28581462-E2E59B39-070E-40B0-8C71-979F592398B6Q28943408-669FB132-FFDC-4E09-85E8-2326CBE8201FQ28943440-BDF3710B-96DA-4D73-97FD-FBA4A788AF02Q30882359-573EEDCD-F863-4A2C-8138-FD0DDA01988FQ33353558-9E594412-5CCA-41FA-B62A-8A4F1187F332Q33601778-8F93F144-9FA9-4108-9C38-D516BFDD6C67Q33624653-70BAD303-E5F0-42CB-89C2-2DB8705DD318Q33663970-DD374A8C-538E-42E4-965A-34E95812AC4BQ33670805-E53620E8-2A20-4767-A1CE-607F61615B9BQ33706685-A8FCAF02-4315-4A35-B8F6-9052CD6CD9E3Q33718730-4C647D17-F39A-4EE6-B0F2-D2C2A820CD2EQ33720760-E0337A88-4BDA-4190-8361-FDB982A6CE5FQ33771694-00255B85-F446-4580-B6DB-DB58AD2100A0Q33836942-C8F13F89-E537-4BBD-AF62-CDBF76B5B826Q34017691-B953A916-8786-401D-91C2-CC4867C1BEC4
P2860
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
description
2005 nî lūn-bûn
@nan
2005 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
@ast
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
@en
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
@nl
type
label
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
@ast
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
@en
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
@nl
prefLabel
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
@ast
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
@en
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
@nl
P2093
P50
P3181
P356
P1433
P1476
Nonsteroidal antiinflammatory drug use and the risk for Parkinson's disease
@en
P2093
Eric Jacobs
Eugenia E Calle
Marjorie L McCullough
Michael J Thun
P3181
P356
10.1002/ANA.20682
P407
P577
2005-12-01T00:00:00Z